Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2026)

Adaptive Biotechnologies has disclosed Capital Expenditures across 9 years of filings, most recently posting $796000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $796000.0, up 277.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (up 28.41% YoY), and the FY2025 annual result was $3.0 million, down 19.24% from the prior year.
• Capital Expenditures came in at $796000.0 for Q1 2026 at Adaptive Biotechnologies, down from $2.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.0 million in Q2 2023 to a low of -$5.3 million in Q3 2023.
• The 5-year median for Capital Expenditures is $344000.0 (2024), against an average of $577941.2.
• Across the five-year window, Capital Expenditures slumped 696.55% in 2023 and soared 2763.75% in 2025, its largest moves.
• Adaptive Biotechnologies' Capital Expenditures stood at -$900000.0 in 2022, then soared by 31.0% to -$621000.0 in 2023, then jumped by 112.88% to $80000.0 in 2024, then jumped by 2763.75% to $2.3 million in 2025, then sank by 65.26% to $796000.0 in 2026.
• The last three Capital Expenditures figures came in at $796000.0 (Q1 2026), $2.3 million (Q4 2025), and $444000.0 (Q3 2025), per Business Quant data.